"In 2018 my lab was working on STING. Noxopharm contacted me to see if I would be interested in conducting research on idronoxil, the active ingredient of Veyonda®. The rationale at the time was that idronoxil would activate the STING pathway, which is involved in anti-tumour immunity. We discovered that idronoxil was a strong inhibitor of STING signalling in late October 2019. This was a key breakthrough. I knew this was the exact opposite of what we had set out to demonstrate for Noxopharm, but I saw the potential of this discovery since it made idronoxil the first human-ready inhibitor of STING signalling."
Think that one through for a minute.
Latest Newsletter, page-3
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
-0.017(14.8%) |
Mkt cap ! $28.63M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 9.8¢ | $70.79K | 680.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25356 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 240399 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |